NCT07713186Not yet recruitingPhase 4
Azithromycin in Atopic Dermatitis
Evaluation of the Value of Adding Azithromycin to Topical Treatment in Mild to Moderate Atopic Dermatitis
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
The study will evaluate the role of adding azithromycin to topical treatment in patients with mild to moderate atopic dermatitis
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 20 Jun 2026
- Start date
- 1 Aug 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- Cairo University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07713186
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 1 Aug 2026 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Atopic dermatitis on active systemic treatment
Who the study is looking for
- Both genders, ages from 3 to 12 years old with mild to moderate atopic dermatitis
Age in the registry: 3 years to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cairo University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.